Publications by authors named "Debparna Saha"
Background: The biotherapeutic asparaginase is a cornerstone of therapy in acute lymphoblastic leukaemia (ALL). With limited access to the original native Escherichia coli-derived asparaginase (EcASNase), a variety of EcASNase biogenerics are used in low-middle-income countries (LMICs). The variable quality of these biogenerics potentially influences clinical outcomes.
View Article and Find Full Text PDFArticle Synopsis
- A study in India assessed bortezomib (BZB) and reduced doses of cytarabine in treating children with relapsed acute lymphoblastic leukemia (rALL), involving 55 participants.
- Out of those treated, 88% achieved second remission and a significant number showed low minimal residual disease after induction therapy.
- The results showed promising one-year survival rates, with 74.7% event-free survival and 79.6% overall survival in the group receiving treatment.
Karyotyping along with a 3-probe fluorescence in situ hybridization (FISH) strategy was used to risk stratify therapy in 303 children with B-cell precursor acute lymphoblastic leukaemia. Of the 166 patients risk stratified, karyotype identified 91 (55%). FISH identified all karyotypes accurately, with the exception of hypodiploidy, and risk stratified an additional 75 patients.
View Article and Find Full Text PDF